+91-8668442535
Home / Healthcare / Polycystic

Polycystic Ovary Syndrome (PCOS) Market By Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, Others) By End User (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online pharmacies) - Growth, Future Prospects & Competitive Analysis, 2016 – 2028

About this report

The global Polycystic Ovary Syndrome (PCOS) Market report explores the critical analysis of the Polycystic Ovary Syndrome (PCOS) industry using key parameters. The report consists of investment strategies, the need for investments in the Polycystic Ovary Syndrome (PCOS) industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the Polycystic Ovary Syndrome (PCOS) industry, as well as how economic and non-economic barriers are helping the Polycystic Ovary Syndrome (PCOS) market grow. Moreover, the report analyzes the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses such as porter's five forces analysis, PESTEL analysis, value chain analysis, etc.

polycystic-ovary-syndrome-(pcos)-market

Key Highlights of the report

How are the major segments performing in the Polycystic Ovary Syndrome (PCOS) Market?

In 2021, the Insulin Sensitizing Agent segment was the leading segment by drug class. Due to their ability to balance hormone levels, reduce ovarian androgen production, and lower insulin levels, insulin-sensitizing drugs are crucial in therapies.

In 2021, the hospital pharmacies led the polycystic ovary syndrome (PCOS) market by end users. Patients always purchase medicines for serious disorders such as polycystic ovary syndrome (PCOS) based on doctors' recommendations in hospitals. 

Which region dominated the Polycystic Ovary Syndrome (PCOS) Market?

In 2021, the market for treating polycystic ovarian syndrome (PCOS) will be dominated by North America due to the region's high level of awareness and accessibility to cutting-edge medical facilities. Due to government measures to increase awareness of the signs and symptoms of PCOS, the diagnosis of this syndrome among women in the region, and the treatments that are accessible, Asia-Pacific is predicted to have high growth during the forecast period.

What is the competitive environment of the Polycystic Ovary Syndrome (PCOS) Market?

The Polycystic Ovary Syndrome (PCOS) industry's competitive environment offers information on the total economic profit made by suppliers and businesses, the sales and revenues produced in this sector, the polycystic ovary syndrome (PCOS) market share globally, the business organization overview, the introduction of new products, and the opportunities for the polycystic ovary syndrome (PCOS) market. Players in the market are focused on developing effective treatments for PCOS. For instance, Abbvie was conducting a clinical trial in women with the polycystic ovarian syndrome to determine the effectiveness and safety of the drug Elagolix in January 2020. Elagolix's safety and effectiveness in treating women with polycystic ovarian syndrome are currently being examined in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study by the company (PCOS).

Executive Summary

What opportunities are for major players in the Polycystic Ovary Syndrome (PCOS) Market?

Most insurance and coverage plans do not cover the cost of drugs used to treat the polycystic ovarian syndrome. Few medications have rather high costs. Adopting polycystic ovarian syndrome medications would benefit from a decrease in the price of branded medications. Only Metformin, an insulin sensitizer, is now on the list of medications that are reimbursed. Drugs for polycystic ovarian syndrome may be covered by reimbursement policies, which would help spur the expansion of the insulin-sensitizing agent's drug class segment, given the high cost of insulin-sensitizing agents in various countries. The development of novel medications to treat polycystic ovarian syndrome is expected to get increased support from government bodies and funding organizations, which will benefit market participants.

Which are the key investments by the players in the Polycystic Ovary Syndrome (PCOS) Market?

Various investments are made throughout by key players through innovation, development of effective treatments, and through strategic collaboration or acquisition. For instance, Abbvie was conducting a clinical trial using the drug Elagolix in women with the polycystic ovarian syndrome in January 2020 to determine its safety and effectiveness. The company is now conducting a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to assess Elagolix's safety and effectiveness in treating women with polycystic ovarian syndrome (PCOS). To develop multiple clinical candidates for the treatment of polycystic ovarian syndrome, which is anticipated to lead the market throughout the projection period, Evotec S.E. and Bayer AG announced a new five-year multi-target cooperation with Celmatix Inc. in January 2020. 

Some of the major players in the market are Allergan plc, AstraZeneca plc, Bayer AG., Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, Teva Pharmaceutical Industries and others.

What are the Major Driving Factors for the Polycystic Ovary Syndrome (PCOS) Market?

Many women of childbearing age experience the hormonal disease of a polycystic ovarian syndrome (PCOS). Menstrual cycles that are irregular or lengthy and increased levels of male hormones are symptoms of polycystic ovary syndrome (PCOS). The market for treating polycystic ovarian syndrome (PCOS) will profit from the rising prevalence of the condition since there will be greater demand for appropriate treatments and pharmaceuticals due to the increased cases of the polycystic ovarian syndrome. As per the Centers for Disease Control and Prevention, Polycystic Ovarian Syndrome affects about 5 million women of reproductive age. Therefore, the increase in cases will immediately present chances for the market to develop profitably during the forecast period.

What Major Risks for the Polycystic Ovary Syndrome (PCOS) Market?

There are several negative effects associated with polycystic ovary syndrome medications. Drug-related side effects include increased insulin resistance, altered glucose tolerance, weight gain, and thromboembolic events predicted to hinder market expansion. The market for treating polycystic ovarian syndrome (PCOS) is expected to have challenges during the forecast period due to a shortage of FDA-approved drugs and approved treatments.

Which is the key drug class in the Polycystic Ovary Syndrome (PCOS) Market?

The largest section consists of insulin-sensitizing agents. Numerous drugs are sold, including Glucophage X.R. (Metformin) and other items containing Troglitazone, Rosiglitazone, and Pioglitazone. Metabolic dysfunction in PCOS may cause an overproduction of androgen, impacting insulin secretion and raising the risk of diabetes. As a result, insulin-sensitizing drugs are crucial for therapies because they balance hormone levels, lower insulin levels, and reduce ovarian androgen production. The market for oral contraceptive pills (OCPs) is anticipated to develop faster. Ethinyl Estradiol, Medroxyprogesterone Acetate, and Drospirenone make up the most commercially available oral contraceptive products. These OCPs treat the symptoms of the polycystic ovarian syndrome, such as acne, severe menstrual pain, PMS, and irregular or nonexistent menstrual cycles. As a result, it is anticipated that demand for OCPs would grow at the quickest rate over the projected period.

How is the Polycystic Ovary Syndrome (PCOS) Market performing in regions?

In 2021, the global Polycystic Ovary Syndrome (PCOS) market was dominated by North America. The most developed market is North America, followed by Europe. One of the major factors driving the market growth in North America is the rise in PCOS cases due to rising rates of obesity and overweight. In addition, more people are becoming aware of the advantages of routine checkups, increasing the number of new cases detected here each year. The United States dominates the North American market with the highest revenue share. This market is expanding mostly due to this nation's huge number of PCOS sufferers. Furthermore, it is projected that the U.S.'s ability to attract large market participants like Merck, Abbott, and BMS will substantially impact the nation's ability to generate income.

China and India comprise most of the population in the Asia Pacific region. As a result, the region's PCOS treatment market has tremendous growth potential due to a sizable target patient pool. The governments of these nations are concentrating on reducing the rising prevalence of PCOS by implementing initiatives that promote the diagnosis, treatment, and necessary lifestyle change of this syndrome. These initiatives raise public awareness of PCOS and its hazards, including the emergence of insulin resistance, obesity, and occasionally infertility. Shortly, the Asia Pacific market is anticipated to be driven by these factors.

What is the regulatory landscape for the Polycystic Ovary Syndrome (PCOS) Market?

The FDA and EMA have not yet approved any medications to treat the polycystic ovarian syndrome, giving pharmaceutical companies a chance to control a sizeable portion of the market. The market for treating polycystic ovarian syndrome (PCOS) is expected to have difficulties due to a shortage of FDA-approved medications and approved treatments.

What is the Market Size of Polycystic Ovary Syndrome (PCOS) regarding value?

The global Polycystic Ovary Syndrome (PCOS) Market is anticipated to grow at a substantial CAGR of 8.4% in the upcoming years. The global Polycystic Ovary Syndrome (PCOS) treatment industry was estimated to be worth USD 3,519.4 million in 2021 and was expected to be worth USD 5,710.1 million by 2028.

What are the major players planning for the future of the Polycystic Ovary Syndrome (PCOS) Market?

The leading competitors in the polycystic ovary syndrome (PCOS) market are substantially investing in technology developments for polycystic ovary syndrome detection, and it is anticipated that the increased awareness of polycystic ovarian syndrome therapy would provide lucrative market prospects. Important players are also concentrating on developing the unrealized potential of developing economies.

Segmentation of Global Polycystic Ovary Syndrome (PCOS) Market-

Global Polycystic Ovary Syndrome (PCOS) Market – By Drug Class

  • Insulin Sensitizing Agent
  • Oral Contraceptive
  • Antiandrogens
  • Anti-Obesity Drugs
  • Others

Global Polycystic Ovary Syndrome (PCOS) Market – By End User

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online pharmacies

Global Polycystic Ovary Syndrome (PCOS) Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Frequently asked questions about the global polycystic ovary syndrome (PCOS) market.

The COVID-19 outbreak had a significant influence on the healthcare industry. The pandemic negatively impacted the market for treating polycystic ovarian syndrome (PCOS), which had an impact on numerous surgical procedures, including laparoscopic ovarian syndrome.

North America accounted for the highest share in the global polycystic ovary syndrome treatment market.

Surging cases of PCOS and expanding the healthcare industry are the major factors driving the market's growth.

Insulin Sensitizing Agent segment had a major market revenue share in 2021. Besides, it is also projected to witness the fastest growth.

The Hospital Pharmacies segment had a major share in the global market in 2021 and is projected to continue its dominance over the forecast period.

Polycystic Ovary Syndrome (PCOS) Market Scope

Report Attribute Details
Market Value in 2021 USD 3,519.4 million
Market Value in 2028 USD 5,710.1 million
CAGR 8.4%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2022
Category:  Healthcare
Report ID:   60699
Report Format:   PDF
Pages:   140
Rating:    4.6 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support